Genomtec S.A.
GMT
Rank in Stocks
#28584
Genomtec S.A., established in 2016 and based in Wroclaw, Poland, is dedicated... Genomtec S.A., established in 2016 and based in Wroclaw, Poland, is dedicated to the research, development, manufacturing, and global commercialization of advanced molecular diagnostic products. The company's expertise lies in optical systems and isothermal nucleic acid amplification methodologies. A core offering is Genomtec ID, a portable technological device designed for on-the-go genetic diagnostics. This system employs streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, fungi, and genetic mutations through the analysis of patient biological materials like swabs, urine, saliva, blood, and other bodily fluids. Furthermore, Genomtec has developed Genomtec Tumor, a SNAAT-based solution for identifying neoplastic mutations and those with prognostic value in cancer diagnoses. The company also offers diagnostic kits for COVID-19, including the Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit, which detects SARS-CoV-2 RNA in samples from individuals suspected of infection, and the Genomtec RT-LAMP CE-IVD Duo-Kit, capable of identifying all variants of the SARS-CoV-2 virus.
Share Price
$0.61787223
Last synced: 2026-11-09
Market Cap
$10.54M
Change (1 day)
-0.36%
Change (1 year)
-55.58%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Genomtec S.A. (GMT)
Category
Healthcare
Operating Margin for Genomtec S.A. (GMT)
Operating Margin as of November 2026 TTM: -37,524.32%
According to Genomtec S.A.'s latest financial reports, its current operating margin (TTM) is -37,524.32%. At the end of 2025 the company had an operating margin of -70,371.43%.
Operating Margin history for Genomtec S.A. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -37,524.32% | -46.68% |
| 2025 | -70,371.43% | -93.63% |
| 2024 | -1,105,500.00% | 26.68% |
| 2023 | -872,700.00% | 2,820.44% |
| 2022 | -29,882.50% | 520.90% |
| 2021 | -4,812.79% | -93.35% |
| 2020 | -72,405.00% | 3,755.78% |
| 2019 | -1,877.83% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.00% |
US
|
|
| 18.08% | -100.00% |
IE
|
|
| 21.25% | -100.00% |
US
|
|
| 21.05% | -100.00% |
US
|
|
| 28.09% | -100.00% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Genomtec S.A.'s operating margin
What is Genomtec S.A.'s operating margin?
Genomtec S.A.'s operating margin is -37,524.32%, as of Nov 2026.
What was Genomtec S.A.'s operating margin in 2025?
In 2025, Genomtec S.A.'s operating margin was -70,371.43%, compared with -1,105,500.00% in 2024.
How has Genomtec S.A.'s operating margin changed since 2020?
From 2020 to 2025, Genomtec S.A.'s operating margin was highest in 2021 (-4,812.79%) and lowest in 2024 (-1,105,500.00%).
How does Genomtec S.A.'s operating margin compare with similar companies?
Genomtec S.A.'s operating margin (-37,524.32%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.